Anaplastic thyroid cancer, tumorigenesis and therapy

Irish Journal of Medical Science

Volumn 179, Issue 1, 2010, Pages 9-15

  O'Neill, J P ^a   Power, D ^b   Condron, C ^a   Bouchier Hayes, D ^a   Walsh, M ^a  

^a BEAUMONT HOSPITAL   (Ireland)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Anaplastic thyroid cancer; Chemotherapy; Oncogene; Post malignant dedifferentiation; Radiotherapy; Surgery; Undifferentiation

Indexed keywords

6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; B RAF KINASE; BETA CATENIN; BEVACIZUMAB; CETUXIMAB; CYCLIN D1; CYCLIN E; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GEMCITABINE; IODINE 131; IRINOTECAN; MULTIDRUG RESISTANCE PROTEIN 1; NAVELBINE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P53; PROTEIN RET; RAS PROTEIN; SODIUM IODIDE SYMPORTER; SORAFENIB; THYROID TRANSCRIPTION FACTOR 1; TRANSCRIPTION FACTOR PAX8; UVOMORULIN; VASCULOTROPIN;

CARCINOGENESIS; DISEASE COURSE; DRUG RESEARCH; DRUG TARGETING; ENZYME INHIBITION; EXTERNAL BEAM RADIOTHERAPY; GENE MUTATION; HUMAN; MEDICAL LITERATURE; MEDLINE; MULTIDRUG RESISTANCE; NONHUMAN; PATIENT CARE; REVIEW; THYROID CANCER; THYROID SCINTISCANNING; THYROID SURGERY;

ANTINEOPLASTIC AGENTS; BETA CATENIN; CADHERINS; CYCLINS; DISEASE PROGRESSION; HUMANS; RADIOTHERAPY; RECEPTOR, EPIDERMAL GROWTH FACTOR; THYROID NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77249129707     PISSN: 00211265     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11845-009-0364-y     Document Type: Review

References (54)

1. C Are AR Shaha 2006 Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches Ann Surg Oncol 13 453 464 10.1245/ASO.2006.05.042 10.1245/ASO.2006.05.042 16474910
2. KB Ain 1998 Anaplastic thyroid carcinoma: behavior, biology, and therapeutic approaches Thyroid 8 715 726 10.1089/thy.1998.8.715 10.1089/thy.1998.8.715 1:STN:280:DyaK1cvgslertA%3D%3D 9737368
3. J Albores-Saavedra DE Henson E Glazer, et al. 2007 Changing patterns in the incidence and survival of thyroid cancer with follicular phenotype-papillary, follicular, and anaplastic: a morphological and epidemiological study Endocr Pathol 18 1 7 10.1007/s12022-007-0002-z 10.1007/s12022-007-0002-z 17652794 (Pubitemid 47345617)
4. TK Kobayashi H Asakawa K Umeshita, et al. 1996 Treatment of 37 patients with anaplastic carcinoma of the thyroid Head Neck 18 36 41 10.1002/(SICI)1097- 0347(199601/02)18:1<36::AID-HED5>3.0.CO;2-# 10.1002/(SICI)1097- 0347(199601/02)18:1<36::AID-HED5>3.0.CO;2-# 1:STN:280:DyaK28zntFSrtw%3D%3D 8774920 (Pubitemid 26002035)
5. TY Kim KW Kim TS Jung, et al. 2007 Prognostic factors for Korean patients with anaplastic thyroid carcinoma Head Neck 29 765 772 10.1002/hed.20578 10.1002/hed.20578 17274052 (Pubitemid 47265532)
6. I Sugitani N Kasai Y Fujimoto, et al. 2001 Prognostic factors and therapeutic strategy for anaplastic carcinoma of the thyroid World J Surg 25 617 622 10.1007/s002680020166 10.1007/s002680020166 1:STN:280: DC%2BD3M3ns1Gjtg%3D%3D 11369989 (Pubitemid 32441436)
7. RA Delellis 2006 Pathology and genetics of thyroid carcinoma J Surg Oncol 94 662 669 10.1002/jso.20700 10.1002/jso.20700 1:CAS:528:DC%2BD2sXislOlsg%3D%3D 17131411 (Pubitemid 44902064)
8. B Saltman B Singh CV Hedvat, et al. 2006 Patterns of expression of cell cycle/apoptosis genes along the spectrum of thyroid carcinoma progression Surgery 140 899 905 10.1016/j.surg.2006.07.027 10.1016/j.surg.2006.07.027 17188136 (Pubitemid 44937378)
9. SM Wiseman TR Loree NR Rigual, et al. 2003 Anaplastic transformation of thyroid cancer: review of clinical, pathologic, and molecular evidence provides new insights into disease biology and future therapy Head Neck 25 662 670 10.1002/hed.10277 10.1002/hed.10277 12884350 (Pubitemid 36909751)
10. SM Wiseman H Masoudi P Niblock, et al. 2007 Anaplastic thyroid carcinoma: expression profile of targets for therapy offers new insights for disease treatment Ann Surg Oncol 14 719 729 10.1245/s10434-006-9178-6 10.1245/s10434-006-9178-6 17115102 (Pubitemid 46175318)
11. SM Wiseman OL Griffith S Deen, et al. 2007 Identification of molecular markers altered during transformation of differentiated into anaplastic thyroid carcinoma Arch Surg 142 727 729
12. MN Nikiforova ET Kimura M Gandhi, et al. 2003 BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas J Clin Endocrinol Metab 88 5399 5404 10.1210/jc.2003-030838 10.1210/jc.2003-030838 1:CAS:528:DC%2BD3sXptVyntrs%3D 14602780 (Pubitemid 37452745)
13. NR Lemoine ES Mayall FS Wyllie, et al. 1989 High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis Oncogene 4 159 164 1:STN:280:DyaL1M7otlWnuw%3D%3D 2648253
14. RM Quiros HG Ding P Gattuso, et al. 2005 Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations Cancer 103 2261 2268 10.1002/cncr.21073 10.1002/cncr.21073 1:CAS:528:DC%2BD2MXlsFSnt70%3D 15880523 (Pubitemid 40686569)
15. DL Segev C Umbricht MA Zeiger 2003 Molecular pathogenesis of thyroid cancer Surg Oncol 12 69 90 10.1016/S0960-7404(03)00037-9 10.1016/S0960-7404(03) 00037-9 12946479 (Pubitemid 37289013)
16. KY Lam CY Lo KW Chan, et al. 2000 Insular and anaplastic carcinoma of the thyroid. A 45 year comparative study at a single institution and review of the significance of p53 and p21 Ann Surg 231 329 338 10.1097/00000658-200003000- 00005 10.1097/00000658-200003000-00005 1:STN:280:DC%2BD3c7nslWjtQ%3D%3D 10714625 (Pubitemid 30137120)
17. F Moretti S Nanni A Farsetti, et al. 2000 Effects of exogenous p53 transduction in thyroid tumor cells with different p53 status J Clin Endocrinol Metab 85 302 308 10.1210/jc.85.1.302 10.1210/jc.85.1.302 1:CAS:528: DC%2BD3cXjtl2mtA%3D%3D 10634403 (Pubitemid 32268830)
18. KM LaPerle SM Jhiang CC Capen 2000 Loss of p53 promotes anaplasia and local invasion in ret/PTC1-induced thyroid carcinomas Am J Pathol 157 671 677 1:CAS:528:DC%2BD3cXlvFyqtro%3D
19. M Nakashima N Takamura H Namba, et al. 2007 RET oncogene amplification in thyroid cancer: correlations with radiation-associated and high grade malignancy Hum Pathol 38 621 628 10.1016/j.humpath.2006.10.013 10.1016/j.humpath.2006.10.013 1:CAS:528:DC%2BD2sXjt1Sht7c%3D 17270245 (Pubitemid 46399890)
20. M Santoro M Papotti G Chiappetta, et al. 2002 RET activation and clinicopathologic features in poorly differentiated thyroid tumors J Clin Endocrinol Metab 87 370 379 10.1210/jc.87.1.370 10.1210/jc.87.1.370 1:CAS:528:DC%2BD38XntVyrsw%3D%3D 11788678 (Pubitemid 34084717)
21. KB Shannon ED Salmon 2002 Chromosome dynamics: new light on Aurora B kinase function Curr Biol 12 458 460 10.1016/S0960-9822(02)00945-4 10.1016/S0960-9822(02)00945-4 (Pubitemid 34766922)
22. S Ulisse JG Delcros E Baldini, et al. 2006 Expression of Aurora kinases in human thyroid carcinoma cell lines and tissues Int J Cancer 119 275 282 10.1002/ijc.21842 10.1002/ijc.21842 1:CAS:528:DC%2BD28XmsVOjt7s%3D 16477625 (Pubitemid 43911890)
23. R Sorrentino S Libertini PL Pallante, et al. 2005 Aurora B overexpression associates with the thyroid carcinoma undifferentiated phenotype and is required for thyroid carcinoma cell proliferation J Clin Endocrinol Metab 90 928 935 10.1210/jc.2004-1518 10.1210/jc.2004-1518 1:CAS:528:DC%2BD2MXhsVCgtrg%3D 15562011 (Pubitemid 40279218)
24. SC Lim MS Lee 2002 Significance of E-cadherin/beta-catenin complex and cyclin D1 in breast cancer Oncol Rep 9 915 928 1:CAS:528:DC%2BD38XmvVegtb0%3D 12168049
25. MC Barton S Akli K Keyomarsi 2006 Deregulation of cyclin E meets dysfunction in p53: closing the escape hatch on breast cancer J Cell Physiol 209 686 694 10.1002/jcp.20818 10.1002/jcp.20818 1:CAS:528:DC%2BD28XhtFOktLrM 17001684 (Pubitemid 44665688)
26. EA Musgrove 2006 Cyclins: roles in mitogenic signaling and oncogenic transformation Growth Factors 24 13 19 10.1080/08977190500361812 10.1080/08977190500361812 1:CAS:528:DC%2BD2MXhtlGht7vE 16393691 (Pubitemid 43108773)
27. JA Fagin K Matsuo A Karmakar, et al. 1993 High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas J Clin Invest 91 179 184 10.1172/JCI116168 10.1172/JCI116168 1:CAS:528:DyaK3sXpvFalsg%3D%3D 8423216
28. G Garcia-Rostan G Tallini A Herrero, et al. 1999 Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma Cancer Res 59 1811 1815 1:CAS:528:DyaK1MXislejsLY%3D 10213482
29. SM Wiseman H Masoudi P Niblock, et al. 2006 Derangement of the E-cadherin/catenin complex is involved in transformation of differentiated to anaplastic thyroid carcinoma Am J Surg 191 581 587 10.1016/j.amjsurg.2006.02.005 10.1016/j.amjsurg.2006.02.005 1:CAS:528:DC%2BD28XjvFSitb0%3D 16647341
30. AS Rocha P Soares E Fonseca J Cameselle-Teijeiro, et al. 2003 E-cadherin loss rather than beta-catenin alterations is a common feature of poorly differentiated thyroid carcinomas Histopathology 42 580 587 10.1046/j.1365-2559. 2003.01642.x 10.1046/j.1365-2559.2003.01642.x 1:STN:280:DC%2BD3szgt1GjsQ%3D%3D 12786894 (Pubitemid 36688152)
31. G Garcia-Rostan RL Camp A Herrero, et al. 2001 Beta-catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis Am J Pathol 158 987 996 1:CAS:528:DC%2BD3MXitlOnu7k%3D 11238046
32. P Hou D Liu Y Shan, et al. 2007 Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer Clin Cancer Res 13 1161 1170 10.1158/1078-0432.CCR-06-1125 10.1158/1078-0432. CCR-06-1125 1:CAS:528:DC%2BD2sXhvF2hsLc%3D 17317825 (Pubitemid 46424056)
33. G Garcia-Rostan AM Costa I Pereira-Castro, et al. 2005 Mutation of the PIK3CA gene in anaplastic thyroid cancer Cancer Res 65 10199 10207 10.1158/0008-5472.CAN-04-4259 10.1158/0008-5472.CAN-04-4259 1:CAS:528: DC%2BD2MXht1WgurbP 16288007 (Pubitemid 41743711)
34. C Ensinger G Spizzo P Moser, et al. 2004 Epidermal growth factor receptor as a novel therapeutic target in anaplastic thyroid carcinomas Ann NY Acad Sci 1030 69 77 10.1196/annals.1329.009 10.1196/annals.1329.009 1:CAS:528: DC%2BD2MXivFKktr8%3D 15659782 (Pubitemid 40378898)
35. G Viglietto D Maglione M Rambaldi, et al. 1995 Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PIGF) associated with malignancy in human thyroid tumors and cell lines Oncogene 11 1569 1579 1:CAS:528:DyaK2MXptVymt7Y%3D 7478581
36. CN Prichard S Kim YD Yazici, et al. 2007 Concurrent cetuximab and bevacizumab therapy in a murine orthotopic model of anaplastic thyroid carcinoma Laryngoscope 117 674 679 10.1097/MLG.0b013e318031055e 10.1097/MLG. 0b013e318031055e 1:CAS:528:DC%2BD2sXjvFCltLg%3D 17429874 (Pubitemid 46559046)
37. S Kim CN Prichard MN Younes, et al. 2006 Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice Clin Cancer Res 12 600 607 10.1158/1078-0432.CCR-05-1325 10.1158/1078-0432.CCR-05-1325 1:CAS:528: DC%2BD28XmtlKgsA%3D%3D 16428506 (Pubitemid 43166155)
38. S Kim BA Schiff OG Yigitbasi, et al. 2005 Targeted molecular therapy of anaplastic thyroid carcinoma with AEE788 Mol Cancer Ther 4 632 640 10.1158/1535-7163.MCT-04-0293 10.1158/1535-7163.MCT-04-0293 1:CAS:528: DC%2BD2MXjtFegsLo%3D 15827337 (Pubitemid 40601845)
39. S Hoffman A Burchert A Wunderlich, et al. 2007 Differential effects of cetuximab and AEE 788 on epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) in thyroid cancer cell lines Endocrine 31 105 113 10.1007/s12020-007-0008-9 10.1007/s12020-007-0008-9 (Pubitemid 350195142)
40. K Yohoi PH Thaker S Yazici, et al. 2005 Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model Cancer Res 65 3716 3725 10.1158/0008-5472. CAN-04-3700 10.1158/0008-5472.CAN-04-3700 (Pubitemid 40616349)
41. S Kim YD Yazici G Calzada, et al. 2007 Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice Mol Cancer Ther 6 1785 1792 10.1158/1535-7163.MCT-06-0595 10.1158/1535-7163.MCT-06-0595 1:CAS:528:DC%2BD2sXmsFCru7g%3D 17575107 (Pubitemid 46954055)
42. JW Smit JP Schroder-van der Elst M Karperien, et al. 2007 Iodide kinetics and experimental (131)I therapy in a xenotransplanted human sodium-iodide symporter-transfected human follicular thyroid carcinoma cell line J Clin Endocrinol Metab 87 1247 1253 10.1210/jc.87.3.1247 10.1210/jc.87.3.1247
43. YJ Hsieh CC Ke RS Liu, et al. 2007 Radioiodide imaging and treatment of ARO cancer xenograft in a mouse model after expression of human sodium iodide symporter Anticancer Res 27 2515 2522 1:CAS:528:DC%2BD2sXpvFChsL4%3D 17695547
44. YJ Lee JK Chung JH Shin, et al. 2004 In vitro and in vivo properties of a human anaplastic thyroid carcinoma cell line transfected with the sodium iodide symporter gene Thyroid 14 889 895 10.1089/thy.2004.14.889 10.1089/thy.2004.14. 889 15671766
45. H Jeong YR Kim KN Kim, et al. 2006 Effect of all-trans retinoic acid on sodium/iodide symporter expression, radioiodine uptake and gene expression profiles in a human anaplastic thyroid carcinoma cell line Nucl Med Biol 33 875 882 10.1016/j.nucmedbio.2006.07.004 10.1016/j.nucmedbio.2006.07.004 1:CAS:528:DC%2BD28XhtVyitr7I 17045167 (Pubitemid 44512130)
46. I Presta F Arturi E Ferretti, et al. 2005 Recovery of NIS expression in thyroid cancer cells by overexpression of Pax8 gene BMC Cancer 5 80 10.1186/1471-2407-5-80 10.1186/1471-2407-5-80 16029487 (Pubitemid 41461053)
47. I Sugawara A Masunaga S Itoyama, et al. 1995 Expression of multidrug resistance-associated protein (MRP) in thyroid cancers Cancer Lett 95 135 138 10.1016/0304-3835(95)03878-z 10.1016/0304-3835(95)03878-Z 1:CAS:528: DyaK2MXnsFWgs74%3D 7656221
48. K Yasuhisa M Shin-ya M Michinori, et al. 2007 Mechanism of multidrug recognition by MDR1/ABCB1 Cancer Sci 98 1303 1310 10.1111/j.1349-7006.2007. 00538.x 10.1111/j.1349-7006.2007.00538.x (Pubitemid 47241749)
49. S Touhey R O'Connor S Plunkett, et al. 2002 Structure-activity relationship of indomethacin analogues for MRP-1, COX-1 and COX-2 inhibition: identification of novel chemotherapeutic drug resistance modulators Eur J Cancer 38 1661 1670 10.1016/S0959-8049(02)00128-4 10.1016/S0959-8049(02)00128-4 1:CAS:528:DC%2BD38Xls1WisLs%3D 12142058 (Pubitemid 34876507)
50. E Brignardello M Gallo I Baldi, et al. 2007 Anaplastic thyroid carcinoma: clinical outcome of 30 consecutive patients referred to a single institution in the past 5 years Eur J Endocrinol 156 425 430 10.1530/EJE-06-0677 10.1530/EJE-06-0677 1:CAS:528:DC%2BD2sXltFaku7g%3D 17389456 (Pubitemid 46672642)
51. E Kebebew FS Greenspan OH Clark, et al. 2005 Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors Cancer 103 1330 1335 10.1002/cncr.20936 10.1002/cncr.20936 15739211 (Pubitemid 40410726)
52. JP Pierie A Muzikansky RD Gaz, et al. 2002 The effect of surgery and radiotherapy on outcome of anaplastic thyroid carcinoma Ann Surg Oncol 9 57 64 10.1245/aso.2002.9.1.57 10.1245/aso.2002.9.1.57 11833496 (Pubitemid 34262898)
53. BH Lang CY Lo 2007 Surgical options in undifferentiated thyroid carcinoma World J Surg 31 969 977 10.1007/s00268-007-0776-7 10.1007/s00268-007-0776-7 17483987 (Pubitemid 46716788)
54. W Voigt T Kegel M Weiss, et al. 2005 Potential activity of paclitaxel, vinorelbine and gemcitabine in anaplastic thyroid carcinoma J Cancer Res Clin Oncol 131 585 590 10.1007/s00432-005-0673-0 10.1007/s00432-005-0673-0 1:CAS:528:DC%2BD2MXhtFGlt7nF 16021466 (Pubitemid 41558551)